1.

Record Nr.

UNINA9910369948503321

Titolo

Novel Therapeutics for Rare Lymphomas / / edited by Christopher Dittus

Pubbl/distr/stampa

Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020

ISBN

3-030-25610-3

Edizione

[1st ed. 2020.]

Descrizione fisica

1 online resource (259 pages)

Disciplina

616.99446059

616.99446

Soggetti

Oncology  

Hematology

Oncology

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

The Hematopathology and Diagnostic Challenges of Rare Lymphomas -- Novel Therapeutics in the Management of Waldenstrom Macroglobulinemia -- Immunotherapy in Hodgkin Lymphoma and other CD30+ Lymphomas -- Chronic Lymphocytic Leukemia with Alterations in TP53 -- Mantel Cell Lymphoma -- Current and Emerging Treatment Strategies from Primary Mediastinal B-Cell Lymphoma -- Plasmablastic Lymphoma and Primary Effusion Lymphoma -- Novel Agents in Primary Central Nervous System Lymphoma -- Adult T-Cell Leukemia/Lymphoma -- Extranodal NK/T-Cell Lymphoma -- Anaplastic Large Cell Lymphoma -- Enteropathy-Associated T-Cell Lymphomas -- Hepatosplenic T-Cell Lymphoma -- Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrom.

Sommario/riassunto

This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they



pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.